Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMWVRHD)

Drug Name
YH002 Drug Info
Indication
Disease Entry ICD 11 Status REF
Aggressive cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMWVRHD

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
OX40L receptor (CD134) TTL31H0 TNR4_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
OX40L receptor (CD134) DTT TNFRSF4 3.413 3.018 2.104 2.888
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Aggressive cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
OX40L receptor (CD134) DTT TNFRSF4 2.17E-06 1.01 1.66
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04353102) A First-in-Human (FIH), Multicenter, Open-Label, Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH002 in Subjects With Advanced Solid Malignancies. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Biocytogen